Detalles de la búsqueda
1.
Autoregressive modeling and diagnostics for qPCR amplification.
Bioinformatics
; 36(22-23): 5386-5391, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33244594
2.
Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders.
Mol Psychiatry
; 25(6): 1275-1285, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31427751
3.
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
Lancet
; 392(10155): 1330-1339, 2018 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30249507
4.
Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
Mod Rheumatol
; 29(2): 306-313, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29532734
5.
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
Ann Rheum Dis
; 77(5): 658-666, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29483080
6.
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
J Pharmacokinet Pharmacodyn
; 45(5): 679-691, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29961161
7.
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.
Mod Rheumatol
; 28(6): 941-949, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29336187
8.
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
Ann Rheum Dis
; 76(12): 2001-2008, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28855173
9.
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Brain Behav Immun
; 66: 156-164, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28676350
10.
Golimumab administered subcutaneously every 4â weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
Ann Rheum Dis
; 74(4): 757-61, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25387477
11.
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ann Rheum Dis
; 74(3): 538-46, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24344160
12.
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 73(9): 1616-25, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24699939
13.
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.
Ann Rheum Dis
; 78(10): 1439-1441, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31018960
14.
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
Ann Rheum Dis
; 73(6): 1107-13, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23644549
15.
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Arthritis Rheum
; 65(10): 2661-71, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23896980
16.
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
Rheumatology (Oxford)
; 52(2): 321-5, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23024015
17.
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Rheumatology (Oxford)
; 52(10): 1845-55, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23838027
18.
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Arthritis Rheum
; 64(7): 2068-77, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22238071
19.
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis.
Ann Rheum Dis
; 71(3): 369-73, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21979001
20.
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
Ann Rheum Dis
; 71(5): 661-7, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22012970